Primary HypercholesterolemiaPhase 3NCT00249249
Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels
A Phase 3 study testing Pitavastatin and Atorvastatin in people with Primary Hypercholesterolemia and Dyslipidemia, run by Kowa Research Europe at 192 sites in 13 countries.
Trial summary
The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Primary Hypercholesterolemia, Dyslipidemia
- What is being tested?
- Pitavastatin and Atorvastatin
- How many people
- 830 participants
- Where
- 192 sitesin 13 countries
- Study dates
- Oct 2005to Nov 2006
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males and females (age 18-75 years).
- Non-pregnant, non-lactating females
- Women of child bearing potential should use sustained contraceptive preparations or an approved mechanical contraceptive method.
- Eligible and able to participate and have given informed consent
- Must have been following a restrictive diet and does not eat or drink grapefruit
- Diagnosis of primary hypercholesterolemia or combined dyslipidemia
- Available for every clinic visit, which will occur in the morning.
Who cannot join
- Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia
- Conditions which may cause secondary dyslipidemia.
- Condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
- History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury
- Liver injury
- Impaired renal function
Show all 29Show fewer
- Current obstruction of the urinary tract or difficulty in voiding due to mechanical as well as inflammatory conditions, which is likely to require intervention during the course of the study or is regarded as clinically meaningful by the investigator
- Serum creatine kinase (CK) >5 x upper limit of the reference range (ULRR).
- Uncontrolled hypothyroidism
- Severe acute illness or severe trauma in the last 3 months
- Major surgery, 3 months prior to Visit 1
- Significant cardiovascular disease (CVD) prior to randomization
- Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response rate of >100 beats per minute at rest.
- Left ventricular (LV) ejection fraction < 0.25
- History of symptomatic cerebrovascular disease
- Conditions at the discretion of the investigator
- Known HIV infection
- Poorly controlled or uncontrolled hypertension.
- Known muscular or neuromuscular disease of any type
- Neoplastic disease
- Drug abuse or continuous consumption of more than 65 mL pure alcohol per day
- Exposure to any investigational new drug within 30 days of study entry or ingestion of any drug known to be toxic to a major organ system
- Current or recent use of supplements known to alter lipid metabolism
- Hypersensitivity reactions to other HMG-CoA reductase inhibitors
- Concomitant medication not permitted
- Resistant to lipid-lowering medications. Known hypersensitivity or intolerance to any lipid lowering agent
- Excessive obesity
- Regular clinic attendance in the morning impractical
- Signs of mental dysfunction or other factors likely to limit ability to cooperate
Trial locations and contacts
192 sites in 13 countries.
192 sites in 13 countries
United Kingdom30 sites
Oldfield Surgery
Bath
St James's Surgery
Bath
St Michael's Partnership
Bath
The Pulteney Practice
Bath
Birmingham Clinical Research Centre
Birmingham
Stonehill Medical Center
Bolton
Avondale Surgery
Chesterfield
Chorley Clinical Research Centre
Chorley
Saltash Health Center
Cornwall
Gomersal Lane Surgery
Dronfield
Townhead Research
Irvine
Crosby Clinical Research Centre
Liverpool
The Symons Medical Center
Maidenhead
Manchester Clinical Research Centre
Manchester
Greenwood Medical Center
Nottingham
Knowle House Surgery
Plymouth
Reading Clinical Research Centre
Reading
Elm Lane Surgery
Sheffield
The Burngreave Surgery
Sheffield
Brook Lane Surgery
Southampton
St Helier Hospital
Surrey
Box Surgery
Wiltshire
Bradford Road Medical Center
Wiltshire
Eastleigh Surgery
Wiltshire
Lovemead Group Practice
Wiltshire
Rowden Medical Partnership
Wiltshire
St Chad's Surgery
Wiltshire
The Health Centre
Wiltshire
The Porch Surgery
Wiltshire
The Burns Medical Practice
Yorkshire
Russia28 sites
Kemerovo Cardiology Dispensary
Kemerovo
Central Clinical Hospital 1 of RZD
Moscow
City Clinical Hospital 23
Moscow
City Clinical Hospital 64
Moscow
Federal State Institution Out-Patient Clinic 3 of Russian Federation of President’s Management
Moscow
Federal State Institution Outpatient Clinic 3 of Russian Federation of President’s Management
Moscow
Moscow City Clinical Hospital 68
Moscow
Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy
Moscow
State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Department of Internal Diseases and Rheumatology based at City Clinica
Moscow
State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40
Moscow
State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department #1 based at City Clinical Hospital # 52
Moscow
State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Development�, Department of Polyclinic Therapy based at Diagnostic Center # 1
Moscow
State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Development�, Department of Therapy based at City Hospital # 4
Moscow
State Educational Institution of Higher Professional Education “Russian State Medical University of Federal Agency of Health Care and Social Development�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Dept
Moscow
State Institution “Research Institute of Physical and Chemical Medicine� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29
Moscow
State Institution “Russian Cardiology Research Complex� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis
Moscow
State Research Center for Preventive Medicine
Moscow
Novosibirsk Reg. Clinical Cardiology Dispensary
Novosibirsk
Central Medical Unit 122, St. Pb
Saint Petersburg
Clinical Hospital of Russian Academy of Sciences
Saint Petersburg
Consulting and Diagnostic Center 85
Saint Petersburg
Krestovsky Island Medical Institute
Saint Petersburg
Pokrovskaya City Hospital
Saint Petersburg
St. Petersburg State Medical Institution “Out-patient Clinic # 109�
Saint Petersburg
St. Petersburg State Medical Institution “Outpatient Clinic # 109�
Saint Petersburg
St. Petersburg State Medical Institution “Pokrovskaya City Hospital�, Cardiology Department #2
Saint Petersburg
State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Chair and Department of Faculty Therapy
Saint Petersburg
State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Institute of Cardiovascular Diseases
Saint Petersburg
India21 sites
Apollo Hospital
Andhra Pradesh, 500033
Care Hospital
Andhra Pradesh, 500034
School of Diabetology, Nizam Institute of Medical Sciences
Andhra Pradesh, 500082
Bhagwan Mahaveer Jain Heart Centre
Bangalore
Sri Ramachandra Medical College Hospital
Chennai
Heart Care Clinic
Gujarat, 380054
Apollo Hospitals
Hyderabaad
CARE Group of Hospitals
Hyderabaad
St. John's Medical College Hospital,
Karnataka, 560034
St. John's Medical College Hospital
Karnataka, 560034
Bathia Hospital
Maharashtra, 400007
LTMMC & General Hospital
Maharashtra, 400022
Sir J. J. Group of Hospitals
Maharashtra, 400027
King Edward Medical College & Hospital
Maharashtra, 411001
Ruby Hall Clinic
Maharashtra, 411001
Lokmanya Hospital
Maharashtra, 411033
PD Hinduja Hospital
Mumbai
Apollo Hospital
New Delhi, 110044
Sir Gagaram Hospital
New Delhi, 110060
Apollo Hospital
Tamil Nadu, 600006
Department of Cardiology
Tamil Nadu, 641004
Germany20 sites
Kardiologische Gemeinschaftspraxis Prof. Reifart
Bad Soden/Taunus
Praxis Dr. Boenninghoff
Beckum
Klinische Forschung Berlin Mitte
Berlin
Gemeinschaftspraxis am Bahnhof
Berlin-Spandau
Pharmakologisches Studienzentum Chemnitz
Chemnitz
GWT-TUK mbH, Zentrum fur Klinische Studien
Dresden
Internistische Diabetische Schwerpunktpraxis Dr.
Frankfurt am Main
Gemeinschaftspraxis Dr. Krause, Th. Menke
Goch
Klinische Forschung Hamburg
Hamburg
Innere Medizin I/Medizinische Klinik
Heidelberg
Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl
Lampertheim
ZET-Studien GmbH Leipzig
Leipzig
Internistische Gemeinschaftspraxis
Mainz
Praxis Dr. Wachter
Mannheim
Gemeinschaftspraxis Melcherstaette
Melcherstaette
Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
Messkirch
Praxisgemeinschaft im Kleinen Biergrund
Offenbach/M
Gemeinschaftspraxis Drs. Mockesch
Weinheim
Intermed Institud Fur Klinische Forschung und Arzn
Wiesbaden
Gemeinschaftspraxis Dr. Emden, Frank Drewes
Worpswede
Netherlands19 sites
Andromed Breda
Breda
Middellaan 5
Breda
Andromed Eindhoven
Eindhoven
Bomanshof 8
Eindhoven
Andromed Noord
Groningen
Damsterdiep 9
Groningen
Vasculair Onderzoek Centrum Hoorn
Hoorn
Andromed Leiden
Leiden
Doezastraat 1
Leiden
Andromed Nijmegen
Nijmegen
Kamerlingh Onnesstraat 16-18
Nijmegen
Andromed Rotterdam
Rotterdam
Mathenesserlaan 247
Rotterdam
Albert Schweitzer Ziekenhuis
Sliedrecht
Andromed Oost
Velp
Reigerstraat 30
Velp
Rivierenland Tiel
Wp Tiel
Andromed Zoetermeer
Zoetermeer
Parkdreef 142
Zoetermeer
Spain19 sites
Hospital de San Vicente
Alicante, 03690
Hospital Santa Creu I Sant Pau,
Barcelona, 08025
Hospital Santa Creu I Sant Pau
Barcelona, 08025
Hospital Universitario de Bellvitge
Barcelona
Hospital Vall d'Hebron
Barcelona
Hospital Universitario Reina Sofia
Córdoba
Hospital Ramon y Cajal
Madrid, 28000
Centro de Especialidades Pedro Gonzalez Bueno
Madrid, 28037
Fundacion Jimenez Diaz
Madrid
Hospital Clinico San Carlos
Madrid
Centro de Salud de Ventanielles
Oviedo, 33010
Hospital Clinico S. Juan de Alicante
San Juan, Alicante
Hospital Marques de Valdecilla
Santander, 3908
Hospital Clinico Universitario de Santiago
Santiago de Compostela
Hospital Virgen del Roci-o
Seville, 41013
Hospital Dr. Peset
Valencia, 46017
Hospital Clinic i Provincial
Villaroel, Barcelona
Hospital Clinico Lozano Blesa
Zaragoza, 50009
Hospital Miguel Servet
Zaragoza, 50009
Italy10 sites
Dipartimento di Medicina Clinica e Biotecnologia Applicata
Bologna
Centro di Ricerca Clinica
Chieti
Gerontologia e Geriatria - Universita degli Studi
Ferrara
Dipartimento di Medicina Interna DIMI
Genova
Universita di Modena e Reggio Emilia, Policlinico
Modena
Dipartimento di Medicina Clinica e Sperimentale
Naples
Medicina Clinica e delle Patologie Emergenti
Palermo
Dipartimento di Medicina Interna e Scienze Biomediche
Parma
U.O Malattie Metaboliche e Diabetologia
Treviglio
Azienda Ospedaliero-Universitaria
Trieste
Poland10 sites
Podlaski Osrodek Kardiologii
Bialystok
NZOZ GCP Dobra Praktyka Lekaska
Gruziadz
NZOZ Terapia Optima
Katowice
NZOZ Esculap, Przychodnia Lekary Rodzinnych
Łosice
NZOZ Centrum, Poradnia Kardiologiczna
Siedlce
Spec. Gab. Lek. Internistyczno-Kardiologicznly
Tarnów
Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego
Tychy
Instytut Zywnosci i Zywienia
Warsaw
Lecznica PROSEN SMO
Warsaw
Szpital Wolski im. Dr A. Gostynskiej
Warsaw
Sweden10 sites
Angelholms Sjukhus, Medicinkliniken
Angelhom
Sahlgrenska University Hospital, Intermedicin
Gothenburg
Hjartmottagningen
Helsingborg
Lakarcentrum Nyponet
Karineholm
Medicinkliniken
Ludvika
Huslakaren i Sandviken
Sandviken
Narsjukhuset Sandviken, Kardiologlab, Medicin
Sandviken
Hjart & Karlcenter
Södertälje
Karolinska Universitetssjukhuset
Stockholm
Hjarthuset AB
Varberg
Israel9 sites
Department of Internal Medicine, Soroka Medical Center
Beersheva
Department of Internal Medicine A, Rambam Medical Center
Haifa
Department of Internal Medicine, Wolfson Medical Center
Holon
Center for Research, Hadassah University Hospital
Jerusalem Ein Kerem
Meir Hospital
Kfar Saba
Department of Medicine, Hadassah Medical Center
Mount Scopus Jerusalem
Department of Internal Medicine, Rivka Sieff Medical Center
Safed
Institute of Metabolic Diseases
Tel Aviv
Institute of Lipid & Atherosclerosis Research
Tel HaShomer
Denmark6 sites
Copenhagen University Hospital
Copenhagen
Medical Center
Copenhagen
Y Forskning, Bispebjerg Hospital
Copenhagen Nv
Frederiks Hospital, Kardiologisk
Frederiksberg
Kolesterollaboratoriet
Hellerup
CCBR A/S
Vejle
Finland5 sites
Geri-Med Oy
Helsinki
Kaisaniemen Laakariasema
Helsinki
keravan Laakarikeskus
Helsinki
SOK-tyoterveyshuolto
Tampere
TYKS University Hospital
Turku
Norway5 sites
Volvat Medisinske Senter
Fredrikstad
Nyomen Legekontor
Kongsberg
Radhuset Spesialistsenter
Oslo
Rikshospitalet - University Hospital
Oslo
Skedsmo Medisinske Senter A.S.
Skedsmokorset
About this study
Official title: Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin.
Read the detailed description
Following a wash-out dietary lead-in period, patients will receive either Atorvastatin or Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing cholesterol levels.
- Conditions
- Primary Hypercholesterolemia, Dyslipidemia
- Being tested
- Pitavastatin, Atorvastatin
- Keywords
- hypercholesterolemia, dyslipidemia, kowa, KRE, pitavastatin, NK-104
- Medical subject headings
- Dyslipidemias, Hypercholesterolemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PitavastatinDrug
AtorvastatinDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12
Measured: Baseline to 12 weeks
Secondary outcomes (11)
Percent Change From Baseline in Total Cholesterol (TC)
Percent change in total cholesterol from baseline to Week 12
Measured: Baseline to 12 Weeks
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)
percent change from baseline in high density lipoprotein-cholesterol (HDL-C)
Measured: Baseline to 12 weeks
TC:HDL-C Ratio
Ratio of mean total cholesterol to mean HDL-C at 12 weeks
Measured: 12 weeks
Triglycerides (TG)
mean triglycerides at 12 weeks
Measured: 12 weeks
Non-HDL:HDL Ratio
Ratio of non-HDL to HDL at 12 weeks
Measured: 12 weeks
Apolipoprotein B (Apo B)
Apolipoprotein B at 12 weeks
Measured: 12 weeks
Apolipoprotein-A1 (Apo-A1)
Apolipoprotein-A1 at 12 weeks
Measured: 12 weeks
Apo-B:Apo-A1 Ratio
Ratio of Apo-B to Apo-A1 at 12 weeks
Measured: 12 weeks
High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks
high sensitivity C-reactive protein (hs-CRP) at 12 weeks
Measured: 12 weeks
Oxidized LDL at 12 Weeks
oxidized low density lipoprotein at 12 weeks
Measured: 12 weeks
National Cholesterol Education Program [NCEP]LDL-C Target Attainment
Number of patients achieving NCEP LDL-C target (LDL-C less than or equal to 130 mg/dL)
Measured: up to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2005 (estimated)
- Study startOct 2005
- Study completionNov 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Primary HypercholesterolemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 830 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kowa Research Europe
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Dragos Budinski, Med Dr., Study director, Kowa Research Europe
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00249249
- Sponsor's protocol ID
- NK-104-301
- Other IDs
- EudraCT number 2005-001000-39
- Status last verified
- Jan 2010
- First submitted
- 4 Nov 2005
- Last updated
- 12 Jan 2010
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
- ClinicalTrials.gov ID
- NCT00249249
- Acronym / sponsor ID
- NK-104-301
- Conditions
- Primary Hypercholesterolemia, Dyslipidemia
- Keywords
- hypercholesterolemia, dyslipidemia, kowa, KRE, pitavastatin, NK-104
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 830 participants (actual)
- Lead sponsor
- Kowa Research EuropeIndustry (pharma, biotech, devices)
- Study start
- Oct 2005
- Study completion
- Nov 2006 (actual)
- First posted
- 7 Nov 2005 (estimated)
- Results
- Posted 16 Dec 2009
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin.
Detailed description
Following a wash-out dietary lead-in period, patients will receive either Atorvastatin or Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing cholesterol levels.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Males and females (age 18-75 years).
- Non-pregnant, non-lactating females
- Women of child bearing potential should use sustained contraceptive preparations or an approved mechanical contraceptive method.
- Eligible and able to participate and have given informed consent
- Must have been following a restrictive diet and does not eat or drink grapefruit
Key exclusion criteria (29 listed)
- Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia
- Conditions which may cause secondary dyslipidemia.
- Condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
- History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury
- Liver injury
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pitavastatin | Drug | – |
| Atorvastatin | Drug | – |
Primary outcome
Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12
Time frame: Baseline to 12 weeks
11 secondary outcomes
Percent Change From Baseline in Total Cholesterol (TC)
Time frame: Baseline to 12 Weeks
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)
Time frame: Baseline to 12 weeks
TC:HDL-C Ratio
Time frame: 12 weeks
Triglycerides (TG)
Time frame: 12 weeks
Non-HDL:HDL Ratio
Time frame: 12 weeks
Apolipoprotein B (Apo B)
Time frame: 12 weeks
Apolipoprotein-A1 (Apo-A1)
Time frame: 12 weeks
Apo-B:Apo-A1 Ratio
Time frame: 12 weeks
High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks
Time frame: 12 weeks
Oxidized LDL at 12 Weeks
Time frame: 12 weeks
National Cholesterol Education Program [NCEP]LDL-C Target Attainment
Time frame: up to 12 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2010.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Primary Hypercholesterolemia
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Recruiting
Food Supplement for Individuals With Polygenic Hypercholesterolaemia
Polygenic Hypercholesterolaemia
Active, not recruiting
Italian Digital Primary Cardiovascular Prevention Study
Healthy Population
RecruitingObservational study
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Primary Hypercholesterolaemia, Mixed Dyslipidemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dragos Budinski, Med Dr. study director
Kowa Research Europe
192 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pitavastatin and Atorvastatin in people with Primary Hypercholesterolemia and Dyslipidemia, run by Kowa Research Europe at 192 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jan 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 192 sites in United Kingdom, Russia, India, Germany, Netherlands and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Dec 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12 (time frame: Baseline to 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2010.